dual GCG/GLP-1 agonist
-
Mazdutide in Chinese Adults with Overweight or Obesity: Phase 3 GLORY-1 Trial Published in The New England Journal of Medicine
Innovent Biologics’ dual GCG/GLP-1 agonist mazdutide demonstrated significant weight loss (14.84% vs. 0.47% placebo) in a Phase 3 trial (GLORY-1) with 610 Chinese adults with obesity over 48 weeks, published in *NEJM*. Over 50% achieved ≥15% weight reduction, alongside improved cardiovascular and liver health. Safety aligned with GLP-1 therapies, with transient gastrointestinal effects. This marks the first NEJM-published metabolic therapy trial from China, signaling the nation’s rise in drug innovation. Experts emphasized mazdutide’s potential in addressing China’s obesity crisis under “Healthy China 2030.” Partnerships with Eli Lilly and ongoing trials aim to expand its use in metabolic diseases.
